T/FIF Portfolio Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : T/FIF Portfolio

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: mike mulhearn who wrote (252)	11/24/1998 1:53:00 AM
From: scaram(o)uche	Read Replies (1) of 1073

>> Schering-Plough has an option to use our lipid vectors with six proprietary genes, beginning with the p53 tumor suppressor gene. << Mike: I would be very interested in learning more about their p53 interests. When it says "proprietary", what does this mean...... proprietary to who, SGP or GZMO? Are ONXX and other companies secure in their pursuits, etc.? I presume that if the gene was proprietary to SGP, that GZMO would be keeping it confidential. But, I'm confused, as there was a Canji/SGP announcement today about an adenoviral p53 rather than p53 delivered by lipid vector. Was the GZMO license required for the adeno work? Anybody know how to clear this ONXX, Introgen, Canji mess up?

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next